1. Circulating pregnancy hormone relaxin as a first trimester biomarker for preeclampsia
- Author
-
Post Uiterweer, E.D. (Emiel D.), Koster, M.P.H. (Maria), Jeyabalan, A. (Arun), Kuc, S. (Sylwia), Siljee, J.E. (Jacqueline), Stewart, D.R. (Dennis R.), Conrad, K.P. (Kirk P.), Franx, A. (Arie), Post Uiterweer, E.D. (Emiel D.), Koster, M.P.H. (Maria), Jeyabalan, A. (Arun), Kuc, S. (Sylwia), Siljee, J.E. (Jacqueline), Stewart, D.R. (Dennis R.), Conrad, K.P. (Kirk P.), and Franx, A. (Arie)
- Abstract
Objective: Preeclampsia, a multi-system hypertensive disorder, is associated with perturbations in the maternal cardiovascular system during early pregnancy. The corpus luteal hormone relaxin, a potent vasodilator, may contribute to physiological circulatory changes especially in early gestation when circulating levels are highest. This study investigated whether first trimester circulating relaxin may be a suitable biomarker for the early prediction of preeclampsia. Methods: Relaxin was initially measured in first-trimester samples of women who developed late-onset preeclamptic (LO-PE; delivery ≥ 34 weeks; n = 33) and uncomplicated pregnancies (n = 25) in Pittsburgh, USA. Subsequently, to expand the group numbers, relaxin was measured in women who developed LO-PE (n = 95), early-onset preeclamptic (EO-PE; delivery < 34 weeks; n = 57), and uncomplicated pregnancies (n = 469) in Utrecht, the Netherlands. Results: In the Pittsburgh subjects, low relaxin levels (lowest centile:
- Published
- 2020
- Full Text
- View/download PDF